Addressing Landscape Intelligence Challenges with AI

This article serves as a technical report discussing the integration of artificial intelligence (AI) and human expertise in addressing landscape intelligence challenges within the life sciences sector. It highlights the economic potential of AI, estimated to generate $60-110 billion annually, and emphasizes the importance of a human-in-the-loop approach to maximize AI's effectiveness. The report outlines the challenges faced by drug developers, particularly the time-consuming manual processes involved in generating landscape intelligence, which is crucial for regulatory and commercialization strategies. It details how AI-enabled solutions, when combined with human expertise, can enhance the efficiency of these processes. The article also presents insights from industry leaders, including Dr.Evidence's CEO, Rose Higgins, on the necessity of domain knowledge in leveraging AI tools effectively. Furthermore, it discusses the role of cross-functional collaboration in improving regulatory strategies and clinical development, and the importance of adapting AI technologies to meet specific industry needs.